Global cancer statistics, CA Cancer J Clin, vol.65, pp.87-108, 2012. ,
and SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma, N Engl J Med, vol.359, pp.378-90, 2008. ,
Targeting the mTOR pathway in hepatocellular carcinoma: current state and future trends, J Hepatol, vol.60, pp.855-65, 2014. ,
Active form of AKT controls cell proliferation and response to apoptosis in hepatocellular carcinoma, Oncol Rep, vol.31, pp.573-80, 2014. ,
Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells, J Pharmacol Exp Ther, vol.337, pp.155-61, 2011. ,
Bufalin Reverses Resistance to Sorafenib by Inhibiting Akt Activation in Hepatocellular Carcinoma: The Role of Endoplasmic Reticulum Stress, PLoS One, vol.10, p.138485, 2015. ,
Structure, regulation and function of PKB/AKT-a major therapeutic target, Biochim Biophys Acta, vol.1697, pp.3-16, 2004. ,
Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29), Ann Oncol, vol.27, pp.856-61, 2016. ,
Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial, JAMA, vol.312, pp.57-67, 2014. ,
Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition, Mol Cancer Ther, vol.8, pp.742-53, 2009. ,
Efficacy of AKT inhibitor ARQ 092 compared with sorafenib in a cirrhotic rat model with hepatocellular carcinoma, Mol Cancer Ther, vol.16, pp.2157-65, 2017. ,
URL : https://hal.archives-ouvertes.fr/inserm-02333028
Development of PI3K inhibitors: lessons learned from early clinical trials, Nat Rev Clin Oncol, vol.10, pp.143-53, 2013. ,
Inhibition of Akt reverses the acquired resistance to sorafenib by switching protective autophagy to autophagic cell death in hepatocellular carcinoma, Mol Cancer Ther, vol.13, pp.1589-98, 2014. ,
Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis, Hepatology, vol.41, pp.307-321, 2005. ,
Blockade of CD47-mediated cathepsin S/protease-activated receptor 2 signaling provides a therapeutic target for hepatocellular carcinoma, Hepatology, vol.60, pp.179-91, 2014. ,
Nuclear factor kappa B-mediated CD47 up-regulation promotes sorafenib resistance and its blockade synergizes the effect of sorafenib in hepatocellular carcinoma in mice, Hepatology, vol.62, pp.534-579, 2015. ,
Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets, Nat Genet, vol.47, pp.505-516, 2015. ,
URL : https://hal.archives-ouvertes.fr/inserm-01159736
Intratumor heterogeneity in hepatocellular carcinoma, Clin Cancer Res, vol.21, pp.1951-61, 2015. ,
Precision medicine for hepatocellular carcinoma: driver mutations and targeted therapy, Oncotarget, vol.8, pp.55715-55745, 2017. ,
Intrahepatic angiogenesis and sinusoidal remodeling in chronic liver disease: new targets for the treatment of portal hypertension?, J Hepatol, vol.53, pp.976-80, 2010. ,
Complementary vascular and matrix regulatory pathways underlie the beneficial mechanism of action of sorafenib in liver fibrosis, Hepatology, vol.54, pp.573-85, 2011. ,
New Insight into the Anti-liver Fibrosis Effect of Multitargeted Tyrosine Kinase Inhibitors: From Molecular Target to Clinical Trials, Front Pharmacol, vol.6, p.300, 2016. ,
Prognostic significance of neutrophil-lymphocyte ratio in hepatocellular carcinoma: a meta-analysis, BMC Cancer, vol.14, p.117, 2014. ,
Prognostic significance of the neutrophil-tolymphocyte ratio in primary liver cancer: a meta-analysis ,
, PLoS One, vol.9, 2014.
ARQ 092, an orally-available, selective AKT inhibitor, attenuates neutrophil-platelet interactions in sickle cell disease, Haematologica, vol.102, pp.246-59, 2017. ,
Tumor-Associated Neutrophils Recruit Macrophages and T-Regulatory Cells to Promote Progression of Hepatocellular Carcinoma and Resistance to Sorafenib, Gastroenterology, vol.150, pp.1646-1658, 2016. ,
NFkappaB1 is a suppressor of neutrophil-driven hepatocellular carcinoma, Nat Commun, vol.6, p.6818, 2015. ,
Progression of fibrosis in patients with chronic viral hepatitis is associated with IL-17(+) neutrophils, Liver Int, vol.36, pp.1116-1140, 2016. ,
Sex Differences in Spontaneous Degranulation Activity of Intrahepatic Natural Killer Cells during Chronic Hepatitis B: Association with Estradiol Levels, Mediators Inflamm, p.3214917, 2017. ,
URL : https://hal.archives-ouvertes.fr/inserm-02333383